dc.contributor.author | Blok, EJ | |
dc.contributor.author | Engels, CC | |
dc.contributor.author | Dekker-Ensink, G | |
dc.contributor.author | Meershoek-Klein Kranenbarg, E | |
dc.contributor.author | Putter, H | |
dc.contributor.author | Smit, VTHBM | |
dc.contributor.author | Liefers, G-J | |
dc.contributor.author | Morden, JP | |
dc.contributor.author | Bliss, JM | |
dc.contributor.author | Coombes, RC | |
dc.contributor.author | Bartlett, JMS | |
dc.contributor.author | Kroep, JR | |
dc.contributor.author | van de Velde, CJH | |
dc.contributor.author | Kuppen, PJK | |
dc.date.accessioned | 2018-06-13T08:04:59Z | |
dc.date.issued | 2018-08-01 | |
dc.identifier.citation | Breast cancer research and treatment, 2018, 171 (1), pp. 65 - 74 | |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1844 | |
dc.identifier.eissn | 1573-7217 | |
dc.identifier.doi | 10.1007/s10549-018-4785-z | |
dc.description.abstract | PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. EXPERIMENTAL DESIGN: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane. The numbers of CD8-positive TILs were analysed for correlations with disease-free survival (DFS) and overall survival (OS). A similar analysis was performed on 2596 patients in the TEAM trial who were randomized between the sequential scheme and the exemestane monotherapy. RESULTS: In the first cohort, patients with low (below median) numbers of CD8-positive TILs had a univariate hazard ratio (HR) for DFS of 0.27 (95% CI 0.13-0.55) in favour of treatment with exemestane, whereas this benefit was not observed in patients with high numbers of CD8-positive TILs (HR 1.34, 95% CI 0.71-2.50, HR for interaction 5.02, p = 0.001). In the second cohort, patients with low numbers of CD8-positive TILs showed a benefit of exemestane treatment on recurrence-free survival (RFS HR 0.67, 95% CI 0.45-0.99), and not with above-median numbers of CD8-positive TILs (HR 0.86, 95% CI 0.59-1.26, HR for interaction 1.29, p = 0.36). CONCLUSIONS: This study is the first to propose the number of CD8-positive TILs as potential predictive markers for endocrine therapy, with the low presence of CD8-positive TILs associated to benefit for exemestane-inclusive therapy. However, treatment-by-marker interactions were only significant in one cohort, indicating the need for further validation. | |
dc.format | Print-Electronic | |
dc.format.extent | 65 - 74 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Lymphocytes, Tumor-Infiltrating | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Antineoplastic Agents, Hormonal | |
dc.subject | Neoplasm Staging | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Combined Modality Therapy | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject | Neoplasm Grading | |
dc.subject | Biomarkers | |
dc.title | Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-07 | |
rioxxterms.versionofrecord | 10.1007/s10549-018-4785-z | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Breast cancer research and treatment | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.volume | 171 | |
pubs.embargo.terms | Not known | |
pubs.oa-location | https://link.springer.com/article/10.1007/s10549-018-4785-z#aboutcontent | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Bliss, Judith | |